Phase 1 Parkinson's disease trials recruiting now

All Parkinson's disease trials, every phase

Other phases for Parkinson's disease

Phase 1 Parkinson's disease trials

• A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study)
  NCT07666022 · Phase: Phase 1 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease
  NCT07195825 · Phase: Phase 1 · Ages: 40 Years to 70 Years · Sex: All (male and female) · 1 location
• A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
  NCT06565195 · Phase: Phase 1 · Ages: 30 Years to 80 Years · Sex: All (male and female) · 16 locations
• A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
  NCT06753331 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 72 Years · Sex: All (male and female) · 2 locations
• A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
  NCT07630545 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 18 locations
• A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease
  NCT07170475 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease
  NCT07543861 · Phase: Phase 1 · Ages: 50 Years and older · Sex: All (male and female) · 1 location
• A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
  NCT06809400 · Phase: Phase 1 · Ages: 30 Years to 85 Years · Sex: All (male and female) · 14 locations
• A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
  NCT06683378 · Phase: Phase 1 · Ages: 45 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
  NCT07604116 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)
  NCT07513441 · Phase: Phase 1 · Ages: 35 Years to 85 Years · Sex: All (male and female) · 4 locations
• A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
  NCT06978920 · Phase: Phase 1 · Ages: 40 Years to 75 Years · Sex: All (male and female) · 1 location
• A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
  NCT06466525 · Phase: Phase 1 · Ages: 30 Years to 89 Years · Sex: All (male and female) · 2 locations
• An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination.
  NCT07777484 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease
  NCT07166757 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
  NCT07064005 · Phase: Phase 1 · Ages: 50 Years to 80 Years · Sex: All (male and female) · 1 location
• First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
  NCT07216066 · Phase: Phase 1 · Ages: 50 Years to 80 Years · Sex: All (male and female) · 2 locations
• PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
  NCT04396873 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 2 locations
• Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
  NCT07371338 · Phase: Phase 1 · Ages: 50 Years to 80 Years · Sex: All (male and female) · 1 location
• Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
  NCT07154511 · Phase: Phase 1, Phase 2 · Ages: 45 Years and older · Sex: All (male and female) · 1 location
• Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease
  NCT07310264 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
  NCT07422675 · Phase: Phase 1 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 6 locations
• Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease
  NCT05901818 · Phase: Phase 1 · Ages: 30 Years to 85 Years · Sex: All (male and female) · 1 location
• Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease
  NCT07572071 · Phase: Phase 1 · Ages: 30 Years to 70 Years · Sex: All (male and female) · 3 locations
• Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
  NCT07461220 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 14 locations
• Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease
  NCT05152394 · Phase: Phase 1 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
  NCT05395624 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 9 locations
• Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)
  NCT07142044 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
  NCT06732180 · Phase: Phase 1 · Ages: 30 Years to 85 Years · Sex: All (male and female) · 7 locations
• Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
  NCT06356662 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease
  NCT07157345 · Phase: Phase 1 · Ages: 40 Years to 65 Years · Sex: All (male and female) · 1 location
• The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease
  NCT07080775 · Phase: Phase 1 · Ages: 50 Years to 75 Years · Sex: All (male and female) · 1 location
• The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
  NCT06167681 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 75 Years · Sex: All (male and female) · 2 locations
• The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
  NCT06608355 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
  NCT03457493 · Phase: Phase 1, Phase 2 · Ages: 30 Years and older · Sex: All (male and female) · 1 location
• This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
  NCT07102342 · Phase: Phase 1, Phase 2 · Ages: 30 Years to 75 Years · Sex: All (male and female) · 1 location
• Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
  NCT06482268 · Phase: Phase 1 · Ages: 40 Years to 75 Years · Sex: All (male and female) · 1 location
• Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
  NCT06687837 · Phase: Phase 1 · Ages: 45 Years to 80 Years · Sex: All (male and female) · 1 location
• Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease
  NCT07557706 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms
  NCT07182058 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• rTMS to Improve Cognition in Parkinson's
  NCT03836950 · Phase: Phase 1, Phase 2 · Ages: 50 Years and older · Sex: All (male and female) · 2 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.